Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

Lingvay, Ildiko; Sumithran, Priya; Cohen, Ricardo; Roux, Carel W. le

doi:10.1016/s0140-6736(21)01919-x

Cited by 325 publications

(254 citation statements)

References 79 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…Approximately 90% of diabetic patients have T2DM, while T1DM represents 10% of all diabetes cases ( Siehler et al, 2021 ). T2DM is an obesity-related disease, and increased dietary monounsaturated fat is linked with a higher risk of T2DM ( Merino et al, 2019 ; Lingvay et al, 2021 ). Thus, combination of HFD and streptozotocin (STZ) is the most frequently used to establish alternative animal model of T2DM ( Srinivasan et al, 2005 ).…”

Section: Hfd/streptozotocin-induced Type 2 Diabetes Mellitusmentioning

confidence: 99%

Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases

et al. 2022

View full text Add to dashboard Cite

Unhealthy diet, in particular high-fat diet (HFD) intake, can cause the development of several metabolic disorders, including obesity, hyperlipidemia, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS). These popular metabolic diseases reduce the quality of life, and induce premature death worldwide. Evidence is accumulating that the gut microbiota is inextricably associated with HFD-induced metabolic disorders, and dietary intervention of gut microbiota is an effective therapeutic strategy for these metabolic dysfunctions. Polysaccharides are polymeric carbohydrate macromolecules and sources of fermentable dietary fiber that exhibit biological activities in the prevention and treatment of HFD-induced metabolic diseases. Of note, natural polysaccharides are among the most potent modulators of the gut microbiota composition. However, the prebiotics-like effects of polysaccharides in treating HFD-induced metabolic diseases remain elusive. In this review, we introduce the critical role of gut microbiota human health and HFD-induced metabolic disorders. Importantly, we review current knowledge about the role of natural polysaccharides in improving HFD-induced metabolic diseases by regulating gut microbiota.

show abstract

Section: Hfd/streptozotocin-induced Type 2 Diabetes Mellitusmentioning

confidence: 99%

Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Obesity is associated with increased morbidity and mortality, and is an established risk factor for the development of insulin resistance and type 2 diabetes [ 30 ]. In brief, excessive caloric intake in combination with physical inactivity contributes to a mismatch between lipid uptake, storage capacities in white adipose tissue and lipid utilization/oxidation/export, which leads to ectopic lipid deposition in muscle and liver [ 31 ].…”

Section: Anti-obesity Effects Of Indymentioning

confidence: 99%

INDY as a Therapeutic Target for Cardio-Metabolic Disease

Pesta

Jordan

2022

Metabolites

View full text Add to dashboard Cite

Decreased expression of the plasma membrane citrate transporter INDY (acronym I’m Not Dead, Yet) promotes longevity and protects from high-fat diet- and aging-induced metabolic derangements. Preventing citrate import into hepatocytes by different strategies can reduce hepatic triglyceride accumulation and improve hepatic insulin sensitivity, even in the absence of effects on body composition. These beneficial effects likely derive from decreased hepatic de novo fatty acid biosynthesis as a result of reduced cytoplasmic citrate levels. While in vivo and in vitro studies show that inhibition of INDY prevents intracellular lipid accumulation, body weight is not affected by organ-specific INDY inhibition. Besides these beneficial metabolic effects, INDY inhibition may also improve blood pressure control through sympathetic nervous system inhibition, partly via reduced peripheral catecholamine synthesis. These effects make INDY a promising candidate with bidirectional benefits for improving both metabolic disease and blood pressure control.

show abstract

“…Bariatric procedure may assist achieving weight loss [80] [81] [82] [83]. However, all subjects undergoing the procedure must be alerted and educated regarding consequences of the procedure.…”

Section: Diet Recommendations (Practical Consideration)mentioning

confidence: 99%

Non-Insulin Therapeutic Option in Management of Diabetes: Life Style Modification; Diet and Exercise

Kabadi¹

2021

JDM

View full text Add to dashboard Cite

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

Cited by 325 publications

References 79 publications

Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases

Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases

INDY as a Therapeutic Target for Cardio-Metabolic Disease

Non-Insulin Therapeutic Option in Management of Diabetes: Life Style Modification; Diet and Exercise

Contact Info

Product

Resources

About